First Choice Neurology

First Choice Neurology

Research Study Shows New Alzheimer’s Drug Slows Cognitive Decline

A late-stage clinical trial was conducted by Biogen and Eisai and the new Alzheimer’s drug they are developing for Alzheimer’s disease slowed the rate of cognitive decline. New Alzheimer’s Drug – Lecanemab The results were strong, and this could offer hope for a new Alzheimer’s drug. The results were strong for the new medication, lecanemab. …

Research Study Shows New Alzheimer’s Drug Slows Cognitive Decline Read More »

World Alzheimer’s Day: Alzheimer’s, Dementia, and the Brain

Today is World Alzheimer’s Day. It’s a day to celebrate to create awareness about the disease and to reduce the stigmatization and lack of information surrounding dementia. While World Alzheimer’s Month offers a longer period of time for Alzheimer’s or dementia associations worldwide to raise awareness, World Alzheimer’s Day marks the focal point of the …

World Alzheimer’s Day: Alzheimer’s, Dementia, and the Brain Read More »

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients

Biogen is providing its new Alzheimer’s drug Aduhelm free to some patients because of slow reviews by Medicare. There is a division among doctors about whether Aduhelm, also known as aducanumab, the $56,000-a-year drug helps patients. There is also uncertainty about reimbursement from Medicare. Aduhelm was approved by the U.S. Food and Drug Administration (FDA) …

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients Read More »

Booster Needed for Delta and Lambda Variants

Scientists may have underestimated the coronavirus. In the beginning, they said mutated versions shouldn’t be much of a problem—until Alpha spiked last fall. Then, Beta made young people sicker. And Gamma reinfected people. Some epidemiologists were cautiously optimistic that the rapid vaccine rollout would tame the variants… until the Delta variant appeared. Delta was first …

Booster Needed for Delta and Lambda Variants Read More »

First Florida Patient to Receive Biogen Aducanumab Infusion

Jeff Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, is scheduled to treat the first patient in Florida with Biogen’s Aducanumab (Aduhelm), a monthly infusion treatment for early-stage Alzheimer’s patients. The drug works to decrease amyloid plaque in the brain, which is a marker for Alzheimer’s disease. According to Dr. …

First Florida Patient to Receive Biogen Aducanumab Infusion Read More »

Lumbar Puncture for Cerebrospinal Fluid is a Vital Tool to Assess Amyloid Build Up in Alzheimer’s

In recent years, research has shown that tests of cerebrospinal fluid (CSF) can be a valuable tool for the detection of hallmark proteins that are involved in diseases that cause dementia. For example, amyloid and tau proteins build up in Alzheimer’s disease, and their levels can be measured in CSF. These abnormalities contribute to the …

Lumbar Puncture for Cerebrospinal Fluid is a Vital Tool to Assess Amyloid Build Up in Alzheimer’s Read More »

Medicare Sees a Growing Demand for Cognitive Assessment with Patients Suffering from Memory Disorders

Dr. Jeff Gelblum, a board-certified Neurologist with First Choice Neurology, makes great use of the cognitive assessment in his daily practice. Gelblum states, “this activity enables me to determine the specific daily impact of dementia on my patients and allows me to implement a meaningful treatment plan. This plan can include medication as well as …

Medicare Sees a Growing Demand for Cognitive Assessment with Patients Suffering from Memory Disorders Read More »

Translate »